

Author index to Volume 5

- Adams M. *See* Fish RG, 527
 Aggarwal SK *et al.* Cisplatin-induced peptic ulcers, vagotomy, adrenal and calcium modulation, 177; *also* Palma JP, 615
 Alberts DS. *See* Shamdas GJ, 10
 Allenbacher A. *See* Meier T, 403
 Andersen LJ. *See* Havsteen H, 410
 Andreotti PE. *See* Hunter EM, 171
 Angioli R. *See* Untch M, 24
 Arikan N. *See* Yaman LS, 95
 Arnold L. *See* Gulliya KS, 557
 Ashizawa T. *See* Tsuruo T, 634
 Atassi G. *See* Pauwels O, 160
 Auersperg M. *See* Jezersek B, 53
 Averette HE. *See* Untch M, 24
 Awada A. *See* Burris III HA, 394
- Bailey SM. *See* Moody CJ, 367
 Bailly C. *See* Kénani A, 199
 Bally MB. *See* Kanter PM, 579
 Banerjee S. *See* Prashar R, 567
 Barrows LR. *See* Swaffar DS, 15
 Ben-Khaial GS & Shah RM. Effects of 5-fluorouracil on collagen synthesis in the developing palate of hamster, 99
 Bianco AR. *See* Tagliaferri P, 379
 Blagosklonny MV & Neckers LM. Oligonucleotides protect cells from the cytotoxicity of several anti-cancer chemotherapeutic drugs, 437
 Boesch D & Loor F. Extended and persistence of P-glycoprotein inhibition in multidrug-resistant P388 cells after exposure to resistance-modifying agents, 229; *also* Jachez B, 313
 Bonfanti M *et al.* Interferon- β does not change the level of O⁶-alkylguanine-DNA alkyltransferase in cancer patients' lymphocytes, 601
 Borsi JD. *See* Paál C, 539
 Botzler C. *See* Meier T, 403
 Bouffard DY *et al.* Enhancement of the antileukemic activity of 5-aza-2'-deoxycytidine by cyclopentenyl cytosine in HL-60 leukemic cells, 223
 Braquet P. *See* Principe P, 329
 Brown TD *et al.* Phase I trial of sulofenur (LY186641) given orally on a daily x 21 schedule, 151
 Brun A. *See* Ceberg CP, 463
 Budillon A. *See* Tagliaferri P, 379
- Bullard GA. *See* Kanter PM, 448; *also* Kanter PM, 579
 Buquet-Fagot C. *See* Fagot D, 548
 Burdett DN & Shah RM. Effects of vincristine on developing hamster embryos, 309
 Burris III HA *et al.* Phase I and pharmacokinetic studies of topotecan administered as a 72 or 120 h continuous infusion, 394; *also* Brown TD, 151; *also* Shimada Y, 202; *also* O'Rourke TJ, 520
- Cagnola J. *See* Brown TD, 151
 Canti G *et al.* Antitumour immunity induced by photodynamic therapy with aluminum disulfonated phthalocyanines and laser light, 443
 Capranico G. *See* Perego P, 645
 Caraglia M. *See* Tagliaferri P, 379
 Carlsson J. *See* Lindström P, 43
 Ceberg CP *et al.* Enhanced boron uptake in RG 2 rat gliomas by electroporation *in vivo*—a new possibility in boron neutron capture therapy, 463
 Çengel M. *See* Šardaš S, 487
 Chagnaud J-L *et al.* Curative effects on rat sarcomas obtained after a treatment combining two monoclonal antibodies, 361
 Chaichik S. *See* Inbar M, 666
 Chandler KJ. *See* Kirkpatrick DL, 467
 Chapman Jr JM. *See* Hall IH, 75
 Chuchkova M. *See* Damianov C, 298
 Cianfriglia M. *See* Jachez B, 655
 Clarke GM. *See* O'Rourke TJ, 520
 Clifford TL. *See* Watson SA, 591
 Cobb PW. *See* Burris III HA, 394
 Cook JA. *See* Liebmann J, 287
 Cooney DA. *See* Kaur G, 213
 Cooper MR. *See* Figg WD, 336
 Cosolo WC *et al.* Lean body mass, body surface area and epirubicin kinetics, 293
 Coulomb H. *See* Principe P, 329
 Craig JB. *See* Brown TD, 151
 Cree IA. *See* Hunter EM, 171
 Csáki C. *See* Paál C, 539
 Cubeddu R. *See* Canti G, 443
- D'Incalci M. *See* Bonfanti M, 601
 Dalmark M. *See* Havsteen H, 410
- Damianov C *et al.* Combined immunotherapy (CEP, M-VEP + BCG) in the treatment of invasive bladder tumors, 298
 Davidson KK. *See* Van Den Berg CL, 573
 de Valk-Bakker V. *See* Hofs HP, 35
 de Grip WJ. *See* Hofs HP, 35
 De La Cruz PS. *See* Van Den Berg CL, 573
 De Bruijn EA. *See* Dirix LY, 343
 Degan D. *See* Shimada Y, 202
 DeJesus A. *See* Pantazis P, 473
 Dirix LY *et al.* Cytotoxic activity of 7-N-(2-((2-(γ -L-glutamylamino)-ethyl)dithio)ethyl)-mitomycin C and metabolites in cell lines with different resistance patterns, 343
 Dubbelman TMAR. *See* Penning LC, 139
- Earhart RH. *See* Shamdas GJ, 10
 Early J. *See* Pantazis P, 473
 Eckardt JR. *See* Burris III HA, 394; *also* O'Rourke TJ, 520
 El Dawi. *See* Shafik A, 650
 El-Metnawy W. *See* Shafik A, 650
 Elfring GL. *See* Shamdas GJ, 10
 Elis A *et al.* Aplastic anemia induced by cyclohexylchloroethylnitrosourea, 105
 Emmer G. *See* Jachez B, 313
 Erdélyi-Tóth V. *See* Paál C, 539
 Erdoğan F. *See* Šardaš S, 487
- Fagot D *et al.* Antiproliferative effects of sodium butyrate in adrimycin-sensitive and -resistant human cancer cell lines, 548
 Faiderbe S. *See* Chagnaud J-L, 361
 Fan SH. *See* Ho BT, 90
 Faussat-Suberville AM. *See* Principe P, 329
 Ferencz T. *See* Paál C, 539
 Fichtinger-Schepman AMJ. *See* Hill DT, 321
 Fields S. *See* Burris III HA, 394; *also* O'Rourke TJ, 520
 Figg WD *et al.* *In vitro* antitumor effect of hydroxyurea on hormone-refractory prostate cancer cells and its potentiation by phenylbutyrate, 336
 Findlay MPN & Leach MO. *In vivo* monitoring of fluoropyrimidine metabolites: magnetic resonance spectroscopy in the evaluation of 5-fluorouracil, 260

- Fish RG *et al.* A dosing scheme for carboplatin in adult cancer patients based upon pre-infusion renal function and platelet count, 527
- Fisher J. *See* Liebmann J, 287
- Fleischmann Jr WR. *See* Jezeršek B, 53
- Fletcher WS. *See* Sondak VK, 147
- Fock M. *See* Meden H, 483
- Fox BW. *See* Hadfield JA, 533
- Franck B. *See* Gulliya KS, 557
- Fukushima M. *See* Sasaki H, 131
- Gazit A. *See* Kaur G, 213
- Geffard M. *See* Chagnaud J-L, 361
- Gerl A. Vascular toxicity associated with chemotherapy for testicular cancer, 607
- Gheuens EEO. *See* Dirix LY, 343
- Giovanella BC. *See* Pantazis P, 473
- Golouh R. *See* Serša G, 69
- Gomi K. *See* Tsuruo T, 634
- Griffiths H. *See* Fish RG, 527
- Grindey GB. *See* Brown TD, 151
- Gulliya KS *et al.* Topoisomerase II-dependent novel antitumor compounds merocil and merodantoin induce apoptosis in Daudi cells, 557
- Hadfield JA *et al.* Structure-activity studies on 2-aryl-4H-3,1-benzoxazin-4-ones, 533
- Hagiwara A *et al.* Reduced toxicity of a new formulation—peplomycin adsorbed on activated carbon particles—in mice, 31; *also* Selective delivery of a greater amount of methotrexate to regional lymph nodes using a new dosage formulation, methotrexate adsorbed on activated carbon particles, in rats, 194
- Hall IH *et al.* The cytotoxic activity of cyclic imido alkyl ethers, thioethers, sulfoxides, sulfones and related derivatives, 75; *also* Hall IH & Wong OT. The cytotoxicity of 3-imino-ioxoisindolines in murine and human tissue culture cells, 207
- Hamilton JM. *See* Brown TD, 151
- Han I *et al.* Cellular accumulation and DNA damage induced by liposomal *cis*-bis-neodecanoato-*trans*-R,R-1,2-diaminocyclohexaneplatinum (II) in LoVo and LoVo/PDD cells, 64
- Hardy J. *See* O'Rourke TJ, 520
- Harstrick A. *See* Hill BT, 321
- Hartmann D. *See* Hunter EM, 171
- Harvey WH. *See* Sondak VK, 147
- Havlin K. *See* Brown TD, 151
- Havsteen H *et al.* On-demand antiemetic treatment with the serotonin antagonist tropisetron in cisplatin-treated cancer patients, 410
- Heiden T. *See* Skog S, 83
- Hénichart J-P. *See* Kénani A, 199
- Hill BT *et al.* Differential formation and enhanced removal of specific cisplatin-DNA adducts in two cisplatin-selected resistant human testicular teratoma sublines, 321
- Hilsenbeck SG. *See* Shimada Y, 202
- Ho BT *et al.* The opioid mechanism of interferon- α action, 90
- Hofs HP *et al.* Concentration and sequence dependent synergism of ethyldehydroxy-sparsomycin in combination with anti-tumor agents, 35
- Holmberg M *et al.* Effects of lovastatin on a human myeloma cell line: increased sensitivity of a multidrug-resistant subline that expresses the 170 kDa P-glycoprotein, 598
- Houssin R. *See* Kénani A, 199
- Hsi S-N. *See* Kiu M-C, 480
- Hunter EM *et al.* The influence of storage on cytotoxic drug activity in an ATP-based chemosensitivity assay, 171
- Huo YY. *See* Ho BT, 90
- Inaba M. *See* Tsuruo T, 634
- Inatomi H. *See* Wu G, 641
- Inbar M *et al.* Chemotherapy-related persistent indirect hyperbilirubinemia, 666
- Inoue S. *See* Yamamoto S, 4242
- Ireland CM. *See* Swaffar DS, 15
- Issels R. *See* Meier T, 403
- Jachez B *et al.* SDZ 280-125: a cyclopeptide endowed with an *in vitro* cyclosporin A-like profile of activity for the reversion of the P-glycoprotein-mediated multidrug resistance of tumor cells, 313; *also* Modulation of human P-glycoprotein epitope expression by temperature and/or resistance-modulating agents, 655
- Jain PT *et al.* A comparison of the antitumor activity of two triaryl-cyclopropyl antiestrogens (compounds 4d and 5c) on human breast cancer cells in culture, 429
- James K. *See* Fish RG, 527
- Jezeršek B *et al.* Interactions of interferon and vinblastine on experimental tumor model melanoma B-16 *in vitro*, 53
- Joseph PE. *See* Nusbaum NJ, 457
- Kaneda Y. *See* Yamamoto S, 424
- Kanter PM *et al.* Preclinical toxicologic evaluation of DENSPM (N^1 , N^{11} -diethylnorspermine) in rats and dogs, 448; *also* Liposome encapsulated vincristine: preclinical toxicologic and pharmacologic comparison with free vincristine and empty liposomes in mice, rats and dogs, 579; *also* Klaich GM, 355
- Karakaya AE. *See* Sardas S, 487
- Kasunic DA. *See* Shamdas GJ, 10
- Katoh A. *See* Lee M, 239
- Kaur G *et al.* Tyrphostin induced growth inhibition: correlation with effect of p210^{bcr-abl} autokinase activity in K562 chronic myelogenous leukemia, 213
- Kawasaki K. *See* Yamamoto S, 424
- Kénani A *et al.* Comparative subcellular distribution of the copper complexes of bleomycin-A₂ and deglyco-bleomycin-A₂, 199
- Khokhar AR. *See* Han I, 64
- King JM. *See* Kanter PM, 448; *also* Kanter PM, 579
- Kirkpatrick DL *et al.* Synthesis and bioreductive potential of a mono N-oxide derivative of the alkylating agent chlorambucil, 467
- Kiss R. *See* Pauwels O, 160
- Kiu M-C *et al.* Transient neurological disturbances induced by the chemotherapy of high-dose methotrexate for osteogenic sarcoma, 480
- Kjær M. *See* Havsteen H, 410
- Klaich GM & Kanter PM. Induction of dog IL-1 by free and liposomal encapsulated doxorubicin, 355; *also* Kanter PM, 579
- Kobayashi S. *See* Tsuruo T, 634
- Koechli O. *See* Untch M, 24
- Koleva P. *See* Damianov C, 298
- Kopecky KJ. *See* Sondak VK, 147
- Koseki Y. *See* Lothstein L, 623
- Kubo K. *See* Yamamoto S, 424
- Kuhn JG. *See* Brown TD, 151; *also* Burris III HA, 394; *also* Meden H, 483; *also* O'Rourke TJ, 520; *also* Van Den Berg CL, 573
- Kumar A. *See* Prashar R, 567
- Lai G-M. *See* Kiu M-C, 480
- Lallemand F. *See* Fagot D, 548
- Larsson R. *See* Holmberg M, 598
- Lattuada D. *See* Canti G, 443
- Laufman LR. *See* Sondak VK, 147
- Leach MO. *See* Findlay MPN, 260
- Lee M *et al.* Interleukin-2 in neoadjuvant therapy potentiates inhibitory activity of 5-fluorouracil and interferon in experimental liver metastases, 239
- Lemmen P. *See* Lindström P, 43
- Levin VA. *See* Ho BT, 90
- Levitzki A. *See* Kaur G, 213
- Lewin F. *See* Skog S, 83
- Lewis A. *See* Moody CJ, 367
- Liaw C-C. *See* Kiu M-C, 480
- Liebmann J *et al.* Cycloheximide inhibits the cytotoxicity of paclitaxel (Taxol®), 287
- Linder D. *See* Hunter EM, 171

- Linström P *et al.* New carborane-based compounds for boron neutron capture therapy: binding and toxicity of ANC-1, DAC-1 and B-Et-11-OMe in cultured human glioma and mouse melanoma cells, 43
- Lishner M. *See* Elis A, 105
- Liu PY. *See* Sondak VK, 147
- Loor F. *See* Boesch D, 229; *also* Jachez B, 313; *also* Jachez B, 655
- Losa G. *See* Bonfanti M, 601
- Lothstein L *et al.* P-glycoprotein overexpression in mouse cells does not correlate with resistance to N-benzyladriamycin-14-valerate (AD 198), 623
- Lu C-S. *See* Kiu M-C, 480
- Lu JG. *See* Ho BT, 90
- Maeda M. *See* Tokuzen R, 419; *also* Yamamoto S, 424
- Magarian RA. *See* Jain PT, 429
- Mahaffey W. *See* Lee M, 239
- Maiche AG. Management of peritoneal effusions with intracavity mitoxantrone or bleomycin, 305
- Maity P. *See* Pal S, 57
- Malmqvist J. *See* Lindström P, 43
- Mangioni C. *See* Bonfanti M, 601
- Marie J-P. *See* Principe P, 329
- Mason M. *See* Fish RG, 527
- Matthews JL. *See* Gulliya KS, 557
- Mayer LD. *See* Kanter PM, 579
- Mayumi T. *See* Yamamoto S, 424
- McCall NA. *See* Figg WD, 336
- McGill JR. *See* Van Den Berg CL, 573
- McGown AT. *See* Hadfield JA, 533
- McKendrick JJ. *See* Cosolo WC, 293
- Meden H *et al.* Effect of recombinant human interleukin-3 (rhIL-3) on persisting chemotherapy-induced thrombocytopenia, 483
- Meier T *et al.* Ifosfamide induced depletion of glutathione in human peripheral blood lymphocytes and protection by mesna, 403
- Mendoza J. *See* Pantazis P, 473
- Merimsky O. *See* Inbar M, 666
- Mester J. *See* Fagot D, 548
- Meyers CA. *See* Ho BT, 90
- Miklav i D. *See* Sersa G, 69
- Miller C. *See* Aggarwal SK, 177
- Mir LM. *See* Ceberg CP, 463
- Mitchell JB. *See* Liebmann J, 287
- Modiano M. *See* Shamdas GJ, 10
- Momparler RL. *See* Bouffard DY, 223
- Momparler LF. *See* Bouffard DY, 223
- Moody CJ *et al.* Cyclopropamitosenes: novel bioreductive anticancer agents—mechanism of action and enzymic reduction, 367
- Morgan DJ. *See* Cosolo WC, 293
- Mueller G. *See* Meier T, 403
- Multhoff G. *See* Meier T, 403
- Muranishi S. *See* Hagiwara A, 31; *also* Hagiwara A, 194
- Muraro R. *See* Tagliaferri P, 379
- Myers CE. *See* Figg WD, 336
- Nagasawa H. *See* Wu G, 641
- Nakagawa S. *See* Yamamoto S, 424
- Neckers LM. *See* Blagosklonny MV, 437
- New P. *See* O'Rourke TJ, 520
- Nguyen T. *See* Han I, 64
- Nicolin A. *See* Canti G, 443
- Novaković S. *See* Jezeršek B, 53
- Nusbaum NJ & Joseph PE. Emergence of resistance to VP-16/cisplatin chemotherapy: study in a lymphoblast model system, 457
- Nygren P. *See* Holmberg M, 598
- O'Rourke TJ *et al.* Phase I clinical trial of ormaplatin (tetraplatin, NSC 363812), 520; *also* Brown TD, 151
- O'Sullivan N. *See* Moody CJ, 367
- Öberg K. Endocrine tumors of the gastrointestinal tract: systemic treatment, 503
- Ohnishi Y. *See* Tsuruo T, 634
- Ohya T. *See* Hagiwara A, 194
- Okada N. *See* Yamamoto S, 424
- Olin Å. *See* Lindström P, 43
- Olsson P. *See* Lindström P, 43
- Osaki K. *See* Hagiwara A, 194
- Ottenheijm HCJ. *See* Hofs HP, 35
- Paál C *et al.* Pharmacokinetic studies on Elobromol in children with brain tumors, 539
- Pal S & Maity P. Anti-tumor efficacy of glutaminase-copper-ATP combination in mice bearing Ehrlich ascites carcinoma, 57
- Palma JP & Aggarwal SK. Cisplatin and carboplatin mediated release of cytolytic factors in murine peritoneal macrophages *in vitro*, 615
- Pantazis P *et al.* Development of resistance in 9-nitro-camptothecin by human leukemia U-937 cells *in vitro* correlates with altered sensitivities to several anticancer drugs, 473
- Pap É. *See* Paál C, 539
- Pauwels O *et al.* Computer-assisted microscope analysis of morphonuclear modifications induced by anticancer antimetabolites in cell lines cultures *in vitro*, 160
- Pavlidis VH. *See* Hadfield JA, 533
- Payne R. *See* Ho BT, 90
- Penning LC & Dubbleman TMAR. Fundamentals of photodynamic therapy: cellular and biochemical aspects, 139
- Pento JT. *See* Jain PT, 429
- Perego P *et al.* Topoisomerase I gene expression and cell sensitivity to camptothecin in human cell lines of different tumor types, 645
- Perez-Soler R. *See* Han I, 64
- Perras JP. *See* Untch M, 24
- Perry JP. *See* Hadfield JA, 533
- Persson BRR. *See* Ceberg CP, 463
- Pettersson J. *See* Lindström P, 43
- Pierce A. *See* Lee M, 239
- Pinto A. *See* Tagliaferri P, 379
- Power J. *See* Shamdas GJ, 10
- Prashar R *et al.* Chemopreventive action by an extract from *Ocimum sanctum* on mouse skin papillomagenesis and its enhancement of skin glutathione S-transferase activity and acid soluble sulfhydryl level, 567
- Principe P *et al.* Flow cytometric monitoring of anthracycline accumulation after anti-neoplastic ether phospholipid treatment, 329
- Rao AR. *See* Prashar R, 567
- Ravid M. *See* Elis A, 105
- Rinaldi DA. *See* Burris III HA, 394
- Rodriguez G. *See* O'Rourke TJ, 520
- Rothenberg M. *See* Shimada Y, 202
- Sakai T. *See* Tsuruo T, 634
- Sakakura C. *See* Hagiwara A, 31; *also* Hagiwara A, 194
- Salford LG. *See* Ceberg CP, 463
- Samid D. *See* Figg WD, 336
- San Antonio JD. *See* Aggarwal SK, 177
- Sandberg C. *See* Holmberg M, 598
- Saneyoshi M. *See* Tokuzen R, 419
- Šardaš S *et al.* Sister chromatid exchange studies for monitoring DNA damage in lymphocytes of malignant lymphoma patients under cytostatic therapy, 487; *also* Šardaš S, 487
- Sartor O. *See* Figg WD, 336
- Sasaki H & Fukushima M. Prostaglandins in the treatment of cancer, 131
- Satterlee WG. *See* Brown TD, 151
- Sausville EA. *See* Kaur G, 213
- Savin H. *See* Elis A, 105
- Sawai K. *See* Hagiwara A, 31; *also* Hagiwara A, 194
- Schally AV. Hypothalamic hormones: from neuroendocrinology to cancer therapy, 115
- Schmoll HJ. *See* Hill BT, 321
- Schneider U. *See* Gulliya KS, 557
- Schroeder HL. *See* Kirkpatrick DL, 467
- Schuler D. *See* Paál C, 539
- Seeman E. *See* Cosolo WC, 293
- Sersa G *et al.* Anti-tumor effect of tumor necrosis factor combined with electrotherapy on mouse sarcoma, 69; *also* Jezeršek B, 53
- Sevin B-U. *See* Untch M, 24

- Shafik A *et al.* Anal submucosal injection: methotrexate concentration in rectal tumor tissue and serum after anal compared with parenteral injection, 650
- Shah RM. *See* Ben-Khaial GS, 99; *also* Burdett DN, 309
- Shamdas GJ *et al.* Phase 1 study of adozelesin (U-73,975) in patients with solid tumors, 10
- Sharma R. *See* Gulliya KS, 557
- Shaw M. *See* Pantazis P, 473
- Shellard SA. *See* Hill BT, 321
- Shelley MD. *See* Fish RG, 527
- Shimada Y *et al.* Activity of CPT-11 (irinotecan hydrochloride), a topoisomerase I inhibitor, against human tumor colony-forming units, 202
- Shoubayashi S. *See* Hagiwara A, 31
- Siderov J & Zalcberg J. Safe administration of oral etoposide after hypersensitivity reaction to intravenous etoposide, 602
- Sjöberg S. *See* Lindström P, 43
- Skog S *et al.* DNA synthesis after combined treatment with cisplatin and 5-fluorouracil of a mouse ascites tumor growing *in vivo*, 83
- Smets LA. Programmed cell death (apoptosis) and response to anti-cancer drugs, 3
- Smith L. *See* Burris III HA, 394
- Sokhansanj A. *See* Aggarwal SK, 177
- Sondak VK *et al.* Didemnin B in metastatic malignant melanoma: a phase II trial of the Southwest Oncology Group, 147
- Soukop M. Clinical experience with intravenous granisetron, 281
- Specht S. *See* Lee M, 239
- Steele RJC. *See* Watson SA, 591
- Stemmler N. *See* Lee M, 239
- Stephens MA. *See* Moody CJ, 367
- Stowe E. *See* Kaur G, 213
- Stratford IJ. *See* Moody CJ, 367
- Subedi AMC. *See* Hunter EM, 171
- Supino R. *See* Perego P, 645
- Sutherland LA. *See* Hunter EM, 171
- Swaffar DS *et al.* A rapid mechanism-based screen to detect potential anti-cancer agents, 15
- Sweatman TW. *See* Lothstein L, 623
- Tagliaferri P *et al.* Pharmacological modulation of peptide growth factor receptor expression on tumor cells as a basis for cancer therapy, 379
- Takahashi T. *See* Hagiwara A, 31; *also* Hagiwara A, 194
- Tansey LW. *See* Ho BT, 90
- Taroni P. *See* Canti G, 443
- Tashiro T. *See* Tsuruo T, 634
- Taverna M. *See* Bonfanti M, 601
- Taverna P. *See* Bonfanti M, 601
- Teague D. *See* Liebmann J, 287
- Terziev T. *See* Damianov C, 298
- Thibault A. *See* Figg WD, 336
- Tokuzen R *et al.* Augmentation of 5-fluoro-2'-deoxyuridine cytotoxicity by 5-phenethyl-2'-deoxyuridine in human gastric cancer cells in culture, 419
- Tomoda H. *See* Hagiwara A, 194
- Tribukait B. *See* Skog S, 83
- Tsujimoto H. *See* Hagiwara A, 194
- Tsunoda S. *See* Wu G, 641
- Tsuruo T *et al.* Evaluation of antitumor activity of navelbine (vinorelbine ditartrate) against human breast carcinoma xenografts based on its pharmacokinetics in nude mice, 634
- Untch A. *See* Untch M, 24
- Untch M *et al.* Comparison of paclitaxel and docetaxel (Taxotere) in gynecologic and breast cancer cell lines with the ATP-cell viability assay, 24
- Valentini G. *See* Canti G, 443
- van Rennes H. *See* Hofs HP, 35
- Van Der Heyden S. *See* Dirix LY, 343
- Van Den Berg CL *et al.* Pharmacokinetics of hydroxyurea in nude mice, 573
- Van Oosterom AT. *See* Dirix LY, 343
- Vandenberg TA. New developments in chemotherapy for metastatic breast cancer, 251
- Von Hoff DD. *See* Brown TD, 151; *also* Shimada Y, 202; *also* Burris III HA, 394; *also* O'Rourke TJ, 520; *also* Van Den Berg CL, 573
- Wagener DJTh. *See* Hofs HP, 35
- Wahl GM. *See* Van Den Berg CL, 573
- Walls RG. *See* Figg WD, 336
- Walsh JT. *See* Van Den Berg CL, 573
- Watson SA *et al.* Inhibitory effects of the gastrin receptor antagonist CR2093 on basal, gastrin-stimulated and growth factor-stimulated growth of the rat pancreatic cell line AR42J, 591
- Weiss GR. *See* O'Rourke TJ, 520
- Werner B. *See* Lindström P, 43
- Whitworth C. *See* Hadfield JA, 533
- Wiesnet M. *See* Meier T, 403
- Wiggins C. *See* Shamdas GJ, 10
- Wong OT. *See* Hall IH, 75; *also* Hall IH, 207
- Workman P. *See* Moody CJ, 367
- Wu G *et al.* Inhibition by Guan-mu-tong (*Caulis aristolochiae manshuriensis*) of the growth of spontaneous mammary tumors in SHN virgin mice, 641
- Yamaguchi M. *See* Hagiwara A, 194
- Yamaguchi T. *See* Tokuzen R, 419
- Yamamoto A. *See* Hagiwara A, 194
- Yamamoto S *et al.* Antimetastatic effects of synthetic peptides containing the core sequence of the type III connecting segment domain (III_{CS}) of fibronectin, 424
- Yaman LS *et al.* Intravesical mitoxantrone for superficial bladder tumors, 95
- Yamashiro Y. *See* Yamamoto S, 424
- Yamori T. *See* Tsuruo T, 634
- Yang L-Y. *See* Han I, 64
- Yang T-S. *See* Kiu M-C, 480
- Yasar B. *See* Yaman LS, 95
- Yoshida M. *See* Tokuzen R, 419
- Yurdakul T. *See* Yaman LS, 95
- Zagonel V. *See* Tagliaferri P, 379
- Zalcberg JR. *See* Cosolo WC, 293; *also* Siderov J, 602
- Zimet AS. *See* Cosolo WC, 293
- Zissis NP. *See* Yaman LS, 95
- Zunino F. *See* Perego P, 645

Key word index to Volume 5

- Acetylcholinesterase, 177
 Acrolein, 403
 Activated carbon, 31, 194
 AD 198, 623
 Adozelesin, 10
 Adrenal, 177
 Adriamycin, 623
 Alkylation, 367
 Aluminum disulfonated
 phthalocyanines (AlS₂Pc),
 443
 Amino-carboranes, 43
 ANC-1, 43
 Anorectum, 650
 Antagonism, 287
 Anthracycline antibiotics, 623
 Anti-microtubule agents, 24
 Anticancer drugs, 429, 615
 Antiemetic(s), 281, 410
 Antimetabolites, 160
 Antineoplastic
 agents, 437
 drugs, 35
 ether phospholipids, 329
 Antisense, 437
 Antitumor, 533
 activity, 115, 131
 immunity, 443
 Antiviral activity, 131
 Aplastic anemia, 105
 Apoptosis, 3, 557
 2-aryl-4*H*-3,1-benzoxazin-4-
 ones, 533
 Ascites tumor, 83
 ATP, 171
 -cell viability assay, 24
 Autoradiography, 177
 5-aza-2'-deoxycytidine, 223

 B-16 melanoma, 53
 B-Et-11-OMe, 43
bcr-abl, 213
 Beagle dog, 355
 Benzo(a)pyrene, 361
 Bioreduction, 367
 Bioreductive, 467
 Bladder
 cancer, 298
 carcinoma, 95
 tumor, 139
 Bleomycin, 199, 305
 Body surface area, 293

 Bombesin/gastrin releasing
 peptide, 115
 Boron, 463
 neutron capture therapy, 43
 Brain tumor, 539
 Breast cancer, 24, 251
 BSH, 43
 Butyrate, 548

c-myc, 548
 Calcium, 177, 557
 Camptothecin, 473, 645
 Cancer, 199, 260
 patients, 527
 Carboplatin, 527, 615
 Carborane, 43
 Carcinoid tumors, 503
 Cell
 culture, 53
 cycle, 3, 287, 548
 death, 139
 kinetic, 160
 membrane, 329
 permeation, 199
 Cellular
 binding, 43
 distribution, 199
 toxicity, 43
 CFU-S, 57
 Chemoprevention, 567
 Chemosensitivity, 171
 Chemosensitizer, 655
 Chemotherapy, 10, 147, 239,
 251, 298, 483, 503, 607,
 650, 666
 Children, 539
 Chinese herbal medicine, 641
 Chlorambucil, 467
 Chloroacetaldehyde, 403
 [³H]choline, 177
 Chronic myelogenous
 leukemia, 213
 Cisplatin, 83, 457, 615
 -induced ulcers, 177
 resistance, 321
 Cloning system, 202
 Clonogenicity, 139
 Collagen synthesis, 99
 Combination
 index, 35
 therapy, 57
 Corticotropin-releasing
 factor, 115

 CPT-11, 202
 Cu-ATP complex, 57
 Cultured cells, 43
 Cyclic imides, 75
 Cycloheximide, 287
 Cyclohexylchloroethyl-
 nitrousurea, 105
 Cyclopentenyl cytosine, 223
 Cyclopropyl antiestrogen, 429
 Cyclosporin A, 229
 Cytokines, 379
 Cytolytic factors, 615
 Cytoprotection, 437
 Cytostatic drugs, 3, 487
 Cytotoxic, 75
 drug, 171
 peptide analogs, 115
 Cytotoxicity, 207

d-amphetamine, 90
 DAC-1, 43
 Developing palate, 99
 Diaminocyclohexane, 64
 Dibromodulcitol, 539
 Didemnin B, 147
 Diethylnorspermine, 448
 Discorhabdin A, 15
 DNA, 57
 double-strand break
 repair, 15
 fragmentation, 557
 synthesis, 75, 83
 dNTP pools, 83
 Docetaxel, 24
 Dogs, 448, 579
 Dosing scheme, 527
 Doxorubicin, 355, 503
 Drug(s), 379
 discrimination, 90
 distribution, 194
 interaction, 437
 resistance, 457
 retention, 229
 therapy, 457
 DT-diaphorase, 367

 EGF-R, 379
 Elastase inhibition, 533
 Electroporabilization, 463
 Electrotherapy, 69
 Emesis, 177
 Endocrine pancreatic
 tumors, 503

 Epirubicin, 293
 Epitope expression, 655
 Estrogen receptors, 429
 Ethylketocyclazocine, 90
 Etoposide, 457
 Exposure time, 343
 Extrachromosomal DNA, 573

 Fibronectin, 424
 Flow cytometry, 329, 473,
 533
 FMCA, 598
 5-fluoro-2'-deoxyuridine
 cytotoxicity, 419
 5-fluorouracil, 83, 99, 260, 503
 Freezing, 171

 Gastric emptying, 177
 Gastrin, 591
 receptor antagonist, 591
 Glioma, 43
 Glutaminase, 57
 Glutathione, 403, 567
 S-transferase, 567
 Granisetron, 281
 Growth curve, 43
 Guan-mu-tong, 641

 Hamster, 99, 309
 Hematoporphyrin
 derivative, 139
 Hemolysis, 151
 High-dose methotrexate, 480
 HL-60, 223
 5-HT₃ antagonists, 410
 Human
 breast cancer, 429
 gastric tumors, 419
 recombinant IFN- A/D, 53
 tumor colony-forming
 units, 202
 Hydroxyurea, 336, 573
 Hyperbilirubinemia, 666
 Hypotension, 448
 Hypoxia, 467

 ICP
 -AES, 43
 -MS, 43
 Ifosfamide, 403
 IL
 -1, 355
 -2-R, 379

- Image analysis, 160
 3-imino-1-oxoindolines, 207
 Immunochemotherapy, 298
 Immunotherapy, 298
In vivo, 83
¹⁹F magnetic resonance spectroscopy, 260
 Interferon, 239
 α -, 90, 503
 Interleukin
 -1, 615
 -2, 239
 -3, 483
 Internal image, 361
 Intravesical, 95
 Irinotecan, 202

 KW-2149, 343

 L-DOPA, 361
 Laminin, 424
 Laser light, 443
 Lean body mass, 293
 Leukemia, 457
 cells, 473
 Leukemic cells, 223
 Lipophilic platinum complexes, 64
 Liposomes, 64, 355, 579
 Lovastatin, 598
 LoVo, 239
 Luminescence, 171
 Luteinizing hormone-releasing hormone, 115
 Lymph node metastasis, 194
 Lymphocytes, 403

 M-16, 343
 M-18, 343
 Macrophage activation, 615
 Malignant lymphoma, 487
 Mammary tumor, 641
 MCF-7 cells, 429
 MDA-MB-231 cells, 429
 MDR, 598
 Mechanisms, 131
 Median effect, 35

 Melanoma, 43, 147
 Mesna, 403
 Metastases, 239
 Metastasis, 424
 Metastatic, 251
 Methemoglobinemia, 151
 Methotrexate, 194, 650
 Mice, 57, 579, 641
 Mitomycin C, 343
 Mitosene, 367
 Mitoxantrone, 95, 305
 Molecular modeling, 533
 Monoclonal anti-idiotypic antibody, 361
 Multidrug resistance, 229, 313, 343, 548, 623, 655
 Multivariate analysis, 160
 Murine, 573
 recombinant IFN- α , 53
 Mutant CHO cells, 15
 Myocardial infarction, 607

N-oxide, 467
 Natural products, 641
 Nausea, 281
 Navelbine, 634
 Neoadjuvant, 239
 Neovascularization, 361
 Neuroendocrine tumors, 503
 Neurotoxicity, 480, 520
 Neutron capture therapy, 463

Ocimum sanctum, 567
 Oligonucleotides, 437
 Opioid-dopamine interaction, 90
 Ormaplatin, 520
 Osteogenic sarcoma, 480
 Ovarian cancer, 24

 P-glycoprotein, 229, 313, 598, 623, 655
 p105 RB, 548
 Paclitaxel, 24, 287
 Pancreatic cancer, 591
 PCNA, 548
 Peplomycin, 31

 Peptic ulcers, 177
 Peptide
 growth factor receptors, 379
 -poly(ethylene glycol) hybrid, 424
 Peritoneal effusion, 305
 pH, 467
 Pharmacokinetics, 394, 539, 573, 579, 634
 Pharmacology, 151
 Phase
 I trial, 10, 151, 394, 520
 II trial, 147
 5-phenethyl-2'-deoxyuridine, 419
 Phenylbutyrate, 336
 Photodynamic therapy (PDT), 139, 443
 Photoproducts, 557
 Photosensitizers, 139
 Platinum-DNA adducts, 321
 Potentiation, 419
 Programmed cell death, 3
 Prostaglandins, 131
 Prostate cancer, 336
 Protein synthesis inhibitors, 35
 Proteins, 57
 Pulmonary embolism, 607
 Purine synthesis inhibition, 75
 Pyrexia, 355

 Rats, 448, 579
 Raynaud's phenomenon, 607
 Rectal tumors, 650
 Repair of DNA damage, 321
 Resistance, 473
 -modulating agents, 313
 Review, 281
 RNA, 57

 Sarcoma, 361
 experimental, 69
 SDZ
 PSC 833, 229, 655
 280-446, 229
 Sensitive and resistant leukemic cells, 329

 Sister chromatid exchanges, 487
 Skin papillomagenesis, 567
 Solid tumors, 394
 Somatostatin, 115
 analog, 503
 Sparsomycin, 35
 Streptozotocin, 503
 Stroke, 607
 Sulfonylurea, 151
 Sulofenur, 151
 Synergy, 53, 591

 Targeting modulation, 379
 Teratogenicity, 309
 Testicular
 cancer, 607
 teratoma cell lines, 321
 Thrombocytopenia, 483, 527
 Thymidylate synthase, 83
 Topoisomerase
 I, 645
 II, 15, 557
 Topotecan, 394
 Toxicity, 31, 448, 579
 Tropisetron, 410
 Tumor
 inhibition, 57
 necrosis factor, 69
 Type I growth factors, 591
 Tyrosine kinase, 213

 U73,975, 10

 Vagotomy, 177
 Viability, 171
 Vinblastine, 53
 Vincristine, 309, 579
 Vomiting, 281

 Wakayin, 15

 Xenograft, 634

Erratum

Anti-Cancer Drugs 1994, 5, pp. 480-482

Case report

Transient neurological disturbances induced by the chemotherapy of high-dose methotrexate for osteogenic sarcoma

Mee-Chou Kiu,¹ Chuang-Chi Liaw,¹ Tsal-Shen Yang,¹ Gi-Ming Lal,¹ Shin-Nun Hsi² and Chin-Song Lu³

The authors' affiliations should read:

¹Division of Hematology–Oncology, Department of Internal Medicine, ²Department of Orthopedic and ³Department of Neurology, Chang Gung Memorial Hospital, 199 Tung Hwa North Road, Taipei, Taiwan, ROC. Tel: (+886) 3 328 1200 extn 2524; Fax: (+886) 3 328 3973.

The publishers apologise for this error.